Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
1 Nederlandse hepatologie in historisch en toekomstig perspectief hoofdstuk lezen eerste hoofdstuk lezen

2009 | OriginalPaper | Hoofdstuk

6 Portale hypertensie

Auteurs : Dr. H.R. van Buuren, Dr. M.J. Coenraad, R.W.C. Scherptong

Gepubliceerd in: Leverziekten

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

In dit hoofdstuk worden de anatomie van het portale veneuze systeem, de regulatie van de portale druk en de oorzaken en classificatie van verhoging van portale druk (portale hypertensie) besproken. Portale hypertensie gaat gepaard met een groot aantal (patho)fysiologische veranderingen en kan leiden tot complicaties die vrijwel alle organen kunnen betreffen (kader 6.1). De meest voorkomende complicaties zijn bloedingen uit oesophagus- en maagvarices, ascites, spontane bacteriële peritonitis en hepatorenaal syndroom.
vorige hoofdstuk 5 Onderzoeksmethoden in de hepatologie
volgende hoofdstuk 7 Leverfalen
Literatuur
1.
Genecin P, Groszmann RJ. The biology of portal hypertension. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. The Liver: Biology and Pathobiology, pp. 1327–1341. New York: Raven press, Ltd., 1994.
2.
Bosch J, Garcia-Pagan JC, Feu F, Rodes J. Portal hypertension. Clinical pathobiology. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. The Liver: Biology and Pathobiology, pp. 1343–1355. New York: Raven press, Ltd., 1994.
3.
Viallet A, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975;69(6):1297–1300.PubMed
4.
Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure,presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419–424.PubMedCrossRef
5.
Lebrec D, De Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980;79:1139–1144.PubMed
6.
Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401–1407.PubMed
7.
Reynolds JD, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. Am J Med 1970; 49:649–657.PubMedCrossRef
8.
Patch D, Armonis A, Sabin C, Christopoulou K, Greenslade L, McCormick A, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 1999;44:264–269.PubMedCentralPubMedCrossRef
9.
Nevens F, Sprengers D, Feu F, Bosch J, Fevery J. Measurement of variceal pressure with an endoscopic pressure sensitive gauge: validation and effect of propranolol therapy in chronic conditions. J Hepatol 1996; 24(1):66–73.PubMedCrossRef
10.
Norton ID, Andrews JC, Kamath PS. Management of ectopic varices. Hepatology 1998;28(4):1154–1158.PubMedCrossRef
11.
McIndoe AH. Vascular lesions of portal hypertension. Arch Path 1928;5:23.
12.
Payen JL, Cales P, Voigt JJ, Barbe S, Pilette C, Dubuisson L, et al.Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995;108(1):138–144.PubMedCrossRef
13.
14.
De Ledinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB,et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut 1999;44(2):270–273.PubMedCentralPubMedCrossRef
15.
Merican I, Sprengers D, McCormick PA, Minoli G, McIntyre N, Burroughs AK. Diurnal pattern of variceal bleeding in cirrhotic patients.J Hepatol 1993;19(1):15–22.PubMedCrossRef
16.
De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43(1):167–176.PubMedCrossRef
17.
Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27(5):1207–1212.PubMedCrossRef
18.
D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38(3):599–612.PubMedCrossRef
19.
20.
Merkel C, Zoli M, Siringo S, Buuren HR van, Magalotti D, Angeli P, et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol 2000;95:2916–2920.CrossRef
21.
De Franchis R, Pascal JP, Ancona E, Burroughs A, Henderson JM, Fleig WE, et al. Definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 1992;15:256–261.PubMedCrossRef
22.
Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-Arbol L, et al. Endoscopic treatment versus endoscopic treatment plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609–615.PubMedCrossRef
23.
Seewald S, Sriram PV, Naga M, Fennerty MB, Boyer J, Oberti F, et al. Cyanoacrylate glue in gastric variceal bleeding. Endoscopy 2002 ;34(11):926–932.PubMedCrossRef
24.
Hubmann R, Bodlaj G, Czompo M, Benko L, Pichler P, Al-Kathib S, et al. The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy 2006;38(9):896–901.PubMedCrossRef
25.
Luca A, D’Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 1999;212(2):411–421.PubMedCrossRef
26.
Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev. 2002(2):CD002907.
27.
Spaander MC, Murad SD, Buuren HR van, Hansen BE, Kuipers EJ, Janssen HL. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a longterm follow-up study. Gastrointest Endosc 2008;67(6): 821–827.PubMedCrossRef
28.
Koklu S, Coban S, Yuksel O, Arhan M. Left-sided portal hypertension. Dig Dis Sci 2007;52(5):1141–1149.PubMedCrossRef
29.
Lebrec D, Benhamou AC. Ectopic varices in portal hypertension. In: Benhamou AC, Lebrec D, editors. Clinics in Gastroenterology: Portal Hypertension, pp. 105–121 London: Saunders, 1985.
30.
31.
Gerbes AL, Gulberg V, Ginès P, Decaux G, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double blind multicenter trial. Gastroenterology 2003;124:933–939.PubMedCrossRef
32.
Ginés P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646–1654.PubMedCrossRef
33.
Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36:1197–1205.PubMedCrossRef
34.
Heuman DM, Abou-Assi SG, Habib A, Williams LM, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802–810.PubMedCrossRef
35.
Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339(8):533–541.PubMedCrossRef
36.
Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996;24(1):233–240.PubMedCrossRef
37.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8(5):1151–1157.PubMedCrossRef
38.
Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35(2):478–491.PubMedCrossRef
39.
Runyon BA. AASLD practice guideline. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39(3):841–856.PubMedCrossRef
40.
Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004;3:CD004889.PubMed
41.
Moreau R, Asselah T, Condat B, De Kerguenec C, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90–94.PubMedCentralPubMedCrossRef
42.
Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006;21(1):303–307.PubMedCrossRef
43.
Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182–191.PubMedCrossRef
44.
Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000;32: 142–153.PubMedCrossRef
45.
46.
Thanopoulou A, Koskinas J, Hadziyannis S. Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. Eur J Int Med 2002;13:194–198.CrossRef
47.
48.
Evans L, Kim W, Poterucha J, Kamath P. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003;37:897–901.PubMedCrossRef
49.
Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993;17:1081–1085.PubMedCrossRef
50.
51.
Almeida J, Galhenage S, Yu J, Kurtovic J, Riodan S. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol 2006;12:1493–1502.PubMedCentralPubMed
52.
Gines P, Rimola A, Planas R, Vargas V, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebocontrolled trial. Hepatology 1990;12:716–724.PubMedCrossRef
53.
Bernard B, Grange J, Khac E, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998;59:54–57.PubMedCrossRef
54.
Ricart E, Soriano G, Novella MT, Ortiz J, et al. Amoxicillin-clavulanic acid versus cefotaxime in therapy of bacterial infections in cirrhotic patients.J Hepatol 2000;32:596–602.PubMedCrossRef
55.
Sort P, Navasa M, Arroyo V, Aldeguer X, et al. Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–409.PubMedCrossRef
56.
Fernandez J, Monteagudo J, Bargllo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627–634.PubMedCrossRef
57.
Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 20:271–279.PubMedCrossRef
58.
Bhattacharya, et al. Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax. J Gastroenterol Hepatol 2001;16:317–321.PubMedCrossRef
59.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56(9):1310–1318.PubMedCentralPubMed
60.
Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935–944.PubMedCrossRef
61.
Gluud L, Kjaer M, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2006;4:CD005162.PubMed
62.
Arroyo V, Terra C, Gines P. New treatments of hepatorenal syndrome. Semin Liver Dis 2006;26:254–264.PubMedCrossRef
63.
Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14: 1363–1368.PubMedCrossRef
64.
Angeli P, Volpin R, Gerunda G, Craighero R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690–1697.PubMedCrossRef
65.
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164–176.PubMedCrossRef
66.
Arroyo V, Guevara M,Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122:1658–1676.PubMedCrossRef
67.
Hadengue A, Gadano A,Moreau R, Giostra E, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565–570.PubMedCrossRef
68.
Halimi C, Bonnard P, Bernard B, Mathurin P, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153–158.PubMedCrossRef
69.
Ortega R, Ginès P, Uriz J, Cárdenas A, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective,nonrandomized study. Hepatology 2002;36:941–948.PubMedCrossRef
70.
Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005;100:879–885.PubMedCrossRef
71.
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55–64.PubMedCrossRef
72.
Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52(3):742–748.PubMedCrossRef
73.
74.
Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363(9419):1461–1468.PubMedCrossRef
75.
Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005;41(5):1122–1129.PubMedCrossRef
76.
Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome – a liver-induced lung vascular disorder. N Engl J Med 2008;358(22):2378–2387.PubMedCrossRef
77.
Huffmyer JL, Nemergut EC. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care 2007;52(8):1030–1036.PubMed
78.
Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28(1):203–218, ix.
79.
80.
Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42(1):68–74.PubMedCrossRef
Metagegevens
Titel
6 Portale hypertensie
Auteurs
Dr. H.R. van Buuren
Dr. M.J. Coenraad
R.W.C. Scherptong
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
Boek
Leverziekten

Print ISBN: 978-90-313-7436-6

Elektronisch ISBN: 978-90-313-7437-3

Copyright: 2009

DOI
https://doi.org/10.1007/978-90-313-7437-3_6